For many patients using semaglutide (marketed as Ozempic) for weight loss, the physical toll of the drug is a secondary concern to the numbers on the scale. New research from Rutgers Health reveals a “straightforward calculus” driving patient behavior: if the medication works, the side effects—no matter how unpleasant—are tolerated.
The study, published in the Journal of Medical Internet Research, suggests that perceived effectiveness is the single strongest predictor of whether a patient will continue treatment, effectively overshadowing the gastrointestinal distress that has become synonymous with the drug.
To move beyond clinical trials and celebrity headlines, Rutgers researchers utilized “infoveillance”—the analysis of publicly available online health data. By reviewing 60 anonymous patient experiences, the team captured a raw, “human-context” look at life on semaglutide.
“Our study cuts through the noise to ask a simple question: What do people actually experience when they use this medication… and what shapes their decision to keep going or stop?” Abanoub Armanious, lead author and epidemiology graduate student at the Rutgers School of Public Health said.
The research highlighted a stark contrast between physical discomfort and patient satisfaction:
- The Tolerance Gap: A staggering 62% of users reported gastrointestinal issues, including nausea and vomiting. However, these symptoms did not significantly lower satisfaction scores or lead patients to quit.
- The Dealbreaker: Patients were far more likely to discontinue the drug if they experienced little to no weight loss or non-gastrointestinal side effects.
- Proven Results: Approximately 67% of respondents reported noticeable weight loss or a significant reduction in food cravings, mirroring results seen in formal clinical trials.
“For many users, the calculus is straightforward: If the drug helps them lose weight, they’re willing to tolerate significant discomfort,” Morgan James, senior author and adjunct assistant professor of psychiatry at Robert Wood Johnson Medical School said.
Semaglutide functions by mimicking hormones that affect both the digestive system and the brain’s reward centers.
- Insulin Regulation: It helps the body release insulin more effectively.
- Gastric Emptying: It slows the rate at which food leaves the stomach, prolonging the feeling of fullness.
- Neural Pathways: It acts on brain regions that control appetite and “food noise,” reducing intense cravings.
The Rutgers team notes that these findings provide a roadmap for healthcare providers. Because patients are highly motivated by results, clinicians can use this data to set realistic expectations.
Understanding that weight loss may plateau over time—and that side effects vary in intensity—can help patients make better long-term decisions about their treatment plans.
